Tumor Volume Change after Chemotheraphy as a Predictive Factor of Disease Free Survival for Osteosarcoma

e17019 Background: Functional imaging, PET and its fusion with anatomical modalities, PET/CT promise to improve detection and characteristic disease. The objective of this study was to evaluate metabolic tumor volume as measured on F-18 FDG-PET/CT and its association with treatment response and prognosis in patients with head and neck cancer. Methods: The study population consisted of patients received neoadjuvant chemotherapy for a maximum of three cycles followed by radiation therapy. Before treatment patients were taken FDG-PET/CT scan, SUVmax, tumor volume, metastasis were recorded. Results: We enrolled 59 patients with stage III ann IV head and neck cancer. The median age was 66 years (range 47–81). There were 32 patients with stage III and 27 with stage IV. The mean SUVmax was 8.8 (range, 1.478). The mean tumor volume was 21.3 cm3 (range, 0.2–170). There was no correlation between tumor volume and SUVmax (correlation coefficient 0.295). Higher SUVmax was not associated with an increased risk of lymph node and distant metastasis at diagnosis (p = 0.968). But higher tumor volume was associated with an increased risk of lymph node and distant metastasis at diagnosis (p = 0.063). The metabolic tumor volume as measured on PET/CT scans was predictor of treatment response and disease -free survival. The response rate were 84% (21/25) for an SUVmax <5.5, 55% (19/34) for an SUVmax > 5.5 (p = 0.038). The disease free survival were 31.1month for an SUVmax <5.5, 4.6months for an SUVmax > 5.5 (p = 0.025). Conclusions: The metabolic tumor volume as measured on F-18FDG-PET/CT is a predictive biomarker of treatment response and disease free survival for patients with head and neck cancer. No significant financial relationships to disclose.

Download Full-text

PSA nadir as a predictive factor for biochemical disease-free survival and overall survival following whole-gland salvage HIFU following radiotherapy failure

Prostate Cancer and Prostatic Diseases ◽

10.1038/pcan.2016.23 ◽

2016 ◽

Vol 19 (3) ◽

pp. 311-316 ◽

Cited By ~ 7

Author(s):

T T Shah ◽

M Peters ◽

A Kanthabalan ◽

N McCartan ◽

Y Fatola ◽

...

Keyword(s):

Overall Survival ◽

Predictive Factor ◽

Disease Free Survival ◽

Free Survival ◽

Salvage Hifu ◽

Psa Nadir ◽

Disease Free ◽

Radiotherapy Failure

Download Full-text

Long-term Benefit of Tumor Volume-Directed Involved Field Radiation Therapy in the Management of Recurrent Ovarian Cancer

International Journal of Gynecological Cancer ◽

10.1097/igc.0000000000000653 ◽

2016 ◽

Vol 26 (4) ◽

pp. 655-660 ◽

Cited By ~ 18

Author(s):

Kevin Albuquerque ◽

Mona Patel ◽

Margaret Liotta ◽

Matthew Harkenrider ◽

Rong Guo ◽

...

Keyword(s):

Ovarian Cancer ◽

Radiation Therapy ◽

Tumor Volume ◽

Disease Free Survival ◽

Recurrent Ovarian Cancer ◽

Free Survival ◽

Field Radiation ◽

Involved Field ◽

Disease Free

ObjectivesThis study aimed to report on long-term effectiveness of involved field radiation therapy (IFRT) in the salvage of localized recurrent ovarian cancer (ROC).MethodsA retrospective analysis of 27 patients with a diagnosis of epithelial ovarian cancer who received tumor volume-directed IFRT for localized extraperitoneal recurrences (either as consolidation after cytoreductive surgery (CRS) or as attempted salvage if unresectable) forms the basis of this report. All patients were heavily pretreated with multiple chemotherapy regimens. Involved field radiation therapy was primarily with external beam (median dose, 50.4 Gy). Local recurrence-free survival (LRFS) was defined as freedom from in-field recurrences and was considered as a measure of effectiveness of radiotherapy. Statistical analyses evaluated association between disease-free survival, overall survival, LRFS, and various prognostic factors. Comparison was also made with a similar but unmatched cohort with localized recurrences salvaged by additional chemotherapy instead of local therapies (NIFRT group).ResultsOf 27 patients, 17 had optimal CRS before RT. The actuarial survival at 5 and 10 years (in parenthesis) from date of radiation were LRFS (70% and 60%), overall survival (30% and 19%), and disease-free survival (33% and 20%). None of the NIFRT patients survived beyond 5 years from initiation of salvage chemotherapy.ConclusionsLong-term follow-up in this selected series confirmed the benefit of IFRT (±CRS) in localized ROC. Chemotherapy salvage in a similar NIFRT group was not equivalent, suggesting a role for locoregional therapies in selected patients with ROC.

Download Full-text

987: Does Pathologic Tumor Volume in Conventional Renal Carcinoma Predict Disease-Free Survival?

The Journal of Urology ◽

10.1016/s0022-5347(18)35143-7 ◽

2005 ◽

Vol 173 (4S) ◽

pp. 267-267

Author(s):

Stephen A. Poon ◽

Mark H. Katz ◽

Aaron E. Katz ◽

Eric T. Goluboff ◽

Carl A. Olsson ◽

...

Keyword(s):

Renal Carcinoma ◽

Tumor Volume ◽

Disease Free Survival ◽

Free Survival ◽

Disease Free

Download Full-text

Prognostic impact of radiology response and tumor volume among patients with locally advanced squamous cell carcinoma of the head and neck (LASCHNC) treated with concomitant chemoradiation

Journal of Clinical Oncology ◽

10.1200/jco.2009.27.15_suppl.e17035 ◽

2009 ◽

Vol 27 (15_suppl) ◽

pp. e17035-e17035

Author(s):

D. Herchenhorn ◽

A. L. Souza ◽

A. M. Souza ◽

E. T. Boasquevisque ◽

E. M. Boasquevisque ◽

...

Keyword(s):

Tumor Volume ◽

Disease Free Survival ◽

Post Treatment ◽

Volume Reduction ◽

Base Line ◽

Prognostic Impact ◽

Free Survival ◽

Treatment Changes ◽

Tumor Volume Reduction ◽

Disease Free

e17035 Background: There are no validated prognostic factors to predict response of chemo/RT in LASCHNC. Tumor volume as well as post-treatment CT radiology response have been studied in small retrospective series. An analysis of tumor volume and CT radiology response-score to endoscopic and pathologic responses as well as disease free survival was performed. Methods: In a single institution phase I-II study LASCHNC of oropharynx, hypopharynx and larynx were treated with concurrent radiation, cisplatin and erlotinib. 34 patients (pts) underwent a base line and post treatment CT (after 6 weeks), endoscopic evaluation and biopsy. Tumor volume was measured by multiplying the longest diameter by 0,523. (Cancer Res Clin Oncol. 2005), CT post-treatment changes score used as proposed by Pamejier et al., using a 3-point CT-score: 1 = expected post-treatment changes; 2 = focal mass with a maximal diameter of < 1 cm and/or asymmetric obliteration of laryngeal tissue planes; 3 = focal mass with a diameter of > 1 cm, or < 50% estimated tumor volume reduction. Results: Median tumor volume (mTV) was 21cm3 (0.3 to 178), median disease free survival (mDFS) in pts with tumor volume greater than mTV was 20.4 months and not reached in patients with tumor volume lower than mTV, log-rank 5.9, p = 0.015. The median tumor volume reduction by CT was 84% (-62 a 100%), 8pts were classified as score 1 (23.5%), 1pt score 2 (2.9%), 25pts score 3 (73%). There was a tendency for shorter DFS for those with a score 3, log-rank 3.05, p = 0.08. With a median follow-up of 24 months, 88% of score 1.2 are alive, versus 56% of score 3. Conclusions: There is a great variability in TV in LASCHNC, small tumor volumes were related to longer DFS and there is no correlation between tumor reduction and post-treatment CT score. No significant financial relationships to disclose.

Download Full-text